October 27, 2021

The Pros and Cons of Compounding

Compounded medications allow for customized, flexible, and precise dosing and are necessary when an FDA-approved drug product is not available or appropriate or for which the usual strength or route of delivery must be altered. At the same time, serious patient illnesses and death have been linked to poor-quality compounded drugs. Read more

Advertisement

FDA Authorizes Moderna, J&J COVID-19 Boosters; Heterologous Boosters

Expansion of COVID-19 booster vaccines with new FDA authorizations adds to the complexity for pharmacists. A half dose is authorized for the Moderna booster, not a full dose as with the Pfizer vaccine, and a shorter wait time for the Johnson and Johnson (J&J) version—2 months instead of 6 months for the other two. In addition, patients coming in for a booster can mix and match, choosing any of the vaccines for a booster. Here are more details

Does Rivaroxaban Present Greater Bleeding Risks Than Other DOACs?

Direct oral coagulants (DOACs) have been around for more than a decade, but much of the research has involved comparisons of the class to warfarin, not comparisons among DOACs themselves. That has changed. Find out what some new studies determined about rivaroxaban when they looked at DOACs in terms of bleeding risk.

Advertisement

USPSTF Draft Advice on Aspirin Use Applies Only to First CV Event Prevention

New draft recommendations from the U.S. Preventive Services Task Force (USPSTF) have caused confusion for patients using aspirin to help prevent cardiovascular events (CVEs). That’s why the industry is seeking to clarify that the advice applies only to the use of aspirin for prevention of a first CVE, and not to patients who have already had a heart attack or clot-related stroke. Here is more information

 
Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -